Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Medicare & Medicaid Issues:

Medicare Advantage (Part C) and Prescription Drug (Part D): Advocated on quality measures and Star Ratings; third-party marketing practices and broker compensation; risk adjustment reform; modernization of network adequacy standards; reforms to Medicare Advantage benchmarks; and Medicare Part C and Part D reporting requirements.

Medicaid: Advocated on implementation of Medicaid provisions in the One Big Beautiful Bill Act, including community engagement and eligibility requirements; advocated for states to use available data to verify eligibility, compliance and exemptions before requiring additional documentation from enrollees.

Dual Eligibles: Advocated for greater integration of Medicare and Medicaid coverage for dual-eligible beneficiaries, including expanded access to and streamlined enrollment in integrated D-SNP models such as FIDE-SNPs and HIDE-SNPs.

Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on prescription drug models and initiatives being developed by the Center for Medicare & Medicaid Innovation; advocated for affordable access to cell and gene therapies, including creation of a national risk-pool model; advocated for patent reform to reduce barriers that delay lower-cost biosimilars and generics from entering the market; advocated for PBM transparency and reforms that increase visibility into fees, rebates and other compensation; advocated for restrictions on direct-to-consumer drug advertising, including ending tax deductions associated with such advertising; advocated for requirements that pharmaceutical manufacturers disclose wholesale acquisition costs in drug advertisements; and advocated for expanded FDA oversight of direct-to-consumer drug advertising.

Prior Authorization: Advocated for electronic prior authorization policies that reduce administrative burden, improve timely access to appropriate care and support patient safety; advocated for reciprocal requirements and accountability for health plans and providers to support effective adoption of electronic prior authorization; advocated for implementation timelines, technical standards and reporting requirements that recognize the operational and resource constraints of smaller, community-based health plans.

Telehealth: Advocated for permanent extension of Medicare telehealth flexibilities and continued access to virtual care; advocated for extension of the Acute Hospital Care at Home waiver program; advocated for removal of unnecessary in-person requirements that limit Medicare beneficiaries access to telehealth services, including behavioral health care.

Provider Directories: Advocated for improved accuracy of provider directories, greater provider accountability for maintaining accurate information and development of a national provider directory at CMS.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

General Health Care Issues:

Prescription Drug Pricing: Advocated on prescription drug costs, including PBM transparency; advocated in support of the Fair Accountability and Innovative Research (FAIR) Act; advocated for patent reform and on access to and utilization of GLP-1 drugs; and advocated for elimination of the separate interchangeability designation for biosimilars.

Mental and Behavioral Health: Advocated for improved access to mental and behavioral health services, including integrated care and tele-mental health; advocated on federal mental health parity requirements.

Prior Authorization: Advocated for electronic prior authorization policies that reduce administrative burden, improve timely access to appropriate care and support patient safety; advocated for reciprocal requirements and accountability for health plans and providers to support effective adoption of electronic prior authorization; advocated for implementation timelines, technical standards and reporting requirements that recognize the operational and resource constraints of smaller, community-based health plans.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes